Novavax, one of the unexpected success stories of the Covid-19 vaccine race, is about to finish enrolling its US trial in record time, bringing it another step closer to fulfilling orders to inoculate 50m Americans.
The 30-year-old biotech — which has never before successfully brought a drug to market — has almost enrolled the 30,000 participants in its US trial, which began in late December, according to its chief executive, Stanley Erck.
Novavax suffered a setback with its manufacturing that meant the trial started six to eight weeks later than planned, but it has made up some ground as participants rushed to join the trial at 115 sites in the US and Mexico.
您已閱讀20%（667字），剩餘80%（2655字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。